{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Dallas&page=51&state=Texas",
    "query": {
      "state": "Texas",
      "city": "Dallas",
      "page": 51
    },
    "page_size": 10
  },
  "pagination": {
    "page": 51,
    "page_size": 10,
    "total_count": 13796,
    "total_pages": 1380,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Dallas&page=52&state=Texas&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Dallas&page=50&state=Texas&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T06:05:24.547Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06856577",
      "title": "Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration (nAMD)",
        "Wet AMD"
      ],
      "interventions": [
        {
          "name": "Ixo-vec",
          "type": "GENETIC"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Adverum Biotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 311,
      "start_date": "2025-02-28",
      "completion_date": "2030-11-23",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-11-19T06:05:24.547Z",
      "location_count": 75,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06856577"
    },
    {
      "nct_id": "NCT00784875",
      "title": "An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Insomnia",
        "Secondary Insomnia"
      ],
      "interventions": [
        {
          "name": "LY2624803",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "zolpidem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 643,
      "start_date": "2008-10",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2012-02-29",
      "last_synced_at": "2026-11-19T06:05:24.547Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00784875"
    },
    {
      "nct_id": "NCT02656329",
      "title": "International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Iobenguane I -123 Injection",
          "type": "DRUG"
        },
        {
          "name": "Implantable Cardioverter Defibrillator",
          "type": "DEVICE"
        },
        {
          "name": "Thyroid blocking",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GE Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 395,
      "start_date": "2015-12-30",
      "completion_date": "2018-05-04",
      "has_results": true,
      "last_update_posted_date": "2019-05-22",
      "last_synced_at": "2026-11-19T06:05:24.547Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • La Mesa, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02656329"
    },
    {
      "nct_id": "NCT04232631",
      "title": "Non-Invasive Testing to Evaluate Wound Healing in Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetic Foot Ulcer"
      ],
      "interventions": [
        {
          "name": "SnapshotNIR, Kent Imaging",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 157,
      "start_date": "2021-04-28",
      "completion_date": "2026-11-02",
      "has_results": false,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-19T06:05:24.547Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04232631"
    },
    {
      "nct_id": "NCT04682431",
      "title": "A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Gynecologic Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Gastric Adenocarcinoma",
        "Lung Adenocarcinoma",
        "Pancreatic Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "PY159 Single agent dose level 1",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 2",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 3",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 4",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 5",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 6",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 7",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose level 1",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose level 2",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose level 3",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose level 4",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose expansion cohort",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 1",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 2",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 3",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 4",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 5",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ikena Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2020-11-10",
      "completion_date": "2023-08-31",
      "has_results": false,
      "last_update_posted_date": "2024-03-22",
      "last_synced_at": "2026-11-19T06:05:24.547Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • San Francisco, California • Santa Monica, California + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04682431"
    },
    {
      "nct_id": "NCT02503345",
      "title": "Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Secondary Hyperoxaluria",
        "Nephrolithiasis",
        "Kidney Stones",
        "Hyperoxaluria",
        "Dietary Hyperoxaluria"
      ],
      "interventions": [
        {
          "name": "ALLN-177 low dose",
          "type": "DRUG"
        },
        {
          "name": "ALLN-177 mid dose",
          "type": "DRUG"
        },
        {
          "name": "ALLN-177 high dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allena Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2015-07",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2018-01-11",
      "last_synced_at": "2026-11-19T06:05:24.547Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Daytona Beach, Florida • Jacksonville, Florida + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02503345"
    },
    {
      "nct_id": "NCT03723395",
      "title": "A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug-drug Interaction"
      ],
      "interventions": [
        {
          "name": "tucatinib",
          "type": "DRUG"
        },
        {
          "name": "itraconazole",
          "type": "DRUG"
        },
        {
          "name": "rifampin",
          "type": "DRUG"
        },
        {
          "name": "gemfibrozil",
          "type": "DRUG"
        },
        {
          "name": "repaglinide",
          "type": "DRUG"
        },
        {
          "name": "tolbutamide",
          "type": "DRUG"
        },
        {
          "name": "midazolam",
          "type": "DRUG"
        },
        {
          "name": "digoxin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 116,
      "start_date": "2018-09-17",
      "completion_date": "2018-12-28",
      "has_results": false,
      "last_update_posted_date": "2019-12-18",
      "last_synced_at": "2026-11-19T06:05:24.547Z",
      "location_count": 2,
      "location_summary": "Daytona Beach, Florida • Dallas, Texas",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03723395"
    },
    {
      "nct_id": "NCT00964795",
      "title": "Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (\"Wet\") Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Intravitreal Aflibercept Injection 2mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 323,
      "start_date": "2009-12",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2015-03-23",
      "last_synced_at": "2026-11-19T06:05:24.547Z",
      "location_count": 115,
      "location_summary": "Birmingham (2 Locations), Alabama • Phoenix (2 Locations), Arizona • Tucson (2 Locations), Arizona + 112 more",
      "locations": [
        {
          "city": "Birmingham (2 Locations)",
          "state": "Alabama"
        },
        {
          "city": "Phoenix (2 Locations)",
          "state": "Arizona"
        },
        {
          "city": "Tucson (2 Locations)",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00964795"
    },
    {
      "nct_id": "NCT02775812",
      "title": "Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2016-11-28",
      "completion_date": "2022-05-20",
      "has_results": false,
      "last_update_posted_date": "2022-06-10",
      "last_synced_at": "2026-11-19T06:05:24.547Z",
      "location_count": 69,
      "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 58 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02775812"
    },
    {
      "nct_id": "NCT01415505",
      "title": "Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Nebivolol, Valsartan and Hydrochlorothiazide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 812,
      "start_date": "2011-08",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2013-06-04",
      "last_synced_at": "2026-11-19T06:05:24.547Z",
      "location_count": 135,
      "location_summary": "Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 113 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01415505"
    }
  ]
}